- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, April 19, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article from The American Journal of Managed Care® (AJMC®) was highlighted by Orthopedics This Week. The article, “Bundled Payments for Joint Replacement Brings Better Outcomes, Lower Costs in NYU Pilot,” covered reports that the 3-year pilot study resulted in the average cost-per-episode dropping by $6708 from the first year of the pilot to the third year, and that NYU’s Department of Orthopaedic Surgery saw reductions in overall length of stay, fewer admissions for follow-up care, and lower readmission rates at the 30-day, 60-day, and 90-day marks.
OBR Oncology’s Wednesday newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Updated ASCO and ASH Guidelines on Managing Anemia Support Safety, Efficacy of Biosimilar ESAs,” covered the updated practice guideline on the use of erythropoiesis-stimulating agents in cancer care, which states that the available literature suggests that biosimilars of epoetin alfa have similar efficacy and safety to reference agents and that biosimilars and their references may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent.
The Center for Biosimilars®’ article “Diverging from US, Canada Approves Biosimilar Rituximab in Both Oncology and Rheumatology Indications” was cited by the Regulatory Affairs Professionals Society. The article reported that last week, Health Canada approved Celltrion and Teva’s biosimilar rituximab, Truxima, for the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More
